Search clinical trials for: non-small cell lung carcinoma (NSCLC)

Total 115647 results

Sun Yat-sen University

Unknown

Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography

Nasopharyngeal Cancer | Non Small Cell Lung Cancer | Liver Metastasis

China
Central European Cooperative Oncology Group

Completed

An Open, Randomized, Multicentre, Phase II Pilot Study

Non-Small Cell Lung Cancer
Instituto Portugues de Oncologia, Francisco Gentil...
AstraZeneca

Recruiting

Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy (IDEAR)

Non-small Cell Lung Cancer

Portugal
Second Affiliated Hospital, School of Medicine,...
Tongji Hospital; Qilu Hospital of Shandong University; First Hospital of China... and other collaborators

Recruiting

A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)

Pembrolizumab | Non-small-lung-cell Cancer, NSCLC

China
Centre hospitalier de l'Université de Montréal...

Active, not recruiting

Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma (FMT-LUMINATE)

Non Small Cell Lung Cancer Metastatic | Advanced Melanoma

Canada
AstraZeneca
Parexel

Completed

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib (ELIOS)

EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Spain, United States, Italy, Korea, Republic of, Malaysia
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Regione Lombardia

Completed

Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial (ONC-MANILA12)

Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV

Italy
Aktion Bronchialkarzinom e.V.
Boehringer Ingelheim

Completed

An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1) (VENUS-1)

Carcinoma, Non-Small-Cell Lung

Germany
Blueprint Medicines Corporation

Terminated

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Neoplasms | Respiratory Tract Diseases | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | Non Small Cell Lung... and other conditions

United States
Newsoara Biopharma Co., Ltd.

Not yet recruiting

HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC

NSCLC Stage IV
Sunshine Lake Pharma Co., Ltd.

Not yet recruiting

Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations

Advanced NSCLC
University Hospital, Essen

Recruiting

Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. (ESPADURVA)

NSCLC, Stage III

Germany
Zhejiang Genfleet Therapeutics Co., Ltd.

Active, not recruiting

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

NSCLC, Stage III

China
Michael Hopp
Boehringer Ingelheim

Active, not recruiting

AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC

Non-squamous NSCLC

Germany
Peking University Cancer Hospital & Institute

Enrolling by invitation

A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.

Locally Advanced NSCLC

China
Molecular Partners AG

Terminated

MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC

EGFR-mutated NSCLC (Disorder)

United States
Sichuan University
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

Stage IV NSCLC

China
Shenzhen People's Hospital

Enrolling by invitation

Significance of MRD After Surgery in Driver Gene-positive and Driver Gene-negative Stage IB-IIA NSCLC

NSCLC MRD ctDNA

China
Yonsei University

Withdrawn

Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)

Stage III NSCLC

Korea, Republic of
Kiang Wu Hospital

Completed

Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients

NSCLC Stage IV

China
Agenus Inc.

Terminated

Study of AGEN1884 With Pembrolizumab in 1L NSCLC

NSCLC Stage IV

New Zealand, Australia
AstraZeneca

Unknown

Epidemiological Study to Describe Non-small-cell Lung Carcinoma (NSCLC) Clinical Management Patterns in MENA. Lung-EPICLIN/ KSA (EPICLIN)

NSCLC Patient Characteristics

Saudi Arabia
Fujian Cancer Hospital

Unknown

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Chemotherapy Effect | NSCLC Stage IV

China
Sanofi

Active, not recruiting

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05) (CARMEN-LC05)

Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Spain, United States, Brazil, Chile, Czechia, France, Hungary, Israel
Universitair Ziekenhuis Brussel

Unknown

Risk-adapted Stereotactic Body Radiotherapy for Early Non-Small Cell Lung Cancer Using the VERO Stereotactic Body Radio Therapy System

Non-Small Cell Lung Carcinoma

Belgium
Lisette Nixon
AstraZeneca

Unknown

Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN) (PIN)

Non-small Cell Lung Cancer

United Kingdom
Tianjin Medical University Cancer Institute and...
Biotech Pharmaceutical Co., Ltd.

Unknown

Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients (NSCLC)

Non-small Cell Lung Cancer

China
NovoCure GmbH

Not yet recruiting

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC (LUNAR-2)

Metastatic Non-small Cell Lung Cancer
Beijing Friendship Hospital
Newish Technology (Beijing) Co., Ltd.

Unknown

Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

China
Maastricht Radiation Oncology

Completed

Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone With Intensity-modulated Radiotherapy (IMRT) for Non Small Cell Lung Cancer (NSCLC) to an Individualised Mean Lung Dose (MLD)

Stage I-III Non-small Cell Lung Cancer

Netherlands
Maastricht Radiation Oncology

Completed

Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone for Patients With Oligo-metastatic Stage IV Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Stage IV (Oligo-metastases)

Netherlands
Regeneron Pharmaceuticals

Recruiting

Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Advanced NSCLC

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Squamous NSCLC

China
Thomas Marron

Recruiting

Dupilumab_Metastatic NSCLC

Metastatic Non-small Cell Lung Cancer

United States
National Taiwan University Hospital

Completed

AUY922 in Patient With Stage IV NSCLC (NSCLC)

Non-small Cell Lung Cancer (NSCLC)

Taiwan
Seagen Inc.

Terminated

A Safety Study of SGN-CD47M in Patients With Solid Tumors

Melanoma | Soft Tissue Sarcoma | Colorectal Cancer | Non-small Cell Lung Carcinoma | Breast Carcinoma | Head and Neck Squamous Cell Carcinoma | Gastric Carcinoma | Ovarian Carcinoma | Exocrine Pancreatic Carcinoma

United States
Vaxon Biotech

Completed

Efficacy Study of Vx001 Vaccine in NSCLC Patients

Non-small Cell Lung Cancer Metastatic

Germany, Greece, Spain, Romania, France, Italy, Czechia, Poland
Genzyme, a Sanofi Company

Completed

Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC

Non Small Cell Lung Cancer
AstraZeneca

Completed

First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia (IPASS)

Non-Small Cell Lung Cancer

Philippines, China, Malaysia, Japan, Hong Kong, Taiwan, Thailand, Indonesia, Singapore
Genentech, Inc.
Roche Pharma AG

Completed

A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer (PENGUIN)

Non-Small Cell Lung Cancer

Australia, United States
Fundación GECP

Active, not recruiting

Atezolizumab Plus Bevacizumab in First Line NSCLC Patients (TELMA)

Non Small Cell Lung Cancer

Spain
Bayer

Completed

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC). (MISSION)

Carcinoma | Non-Small-Cell Lung

Italy, Spain, China, Korea, Republic of, Bulgaria, Turkey, Greece, Philippines, Taiwan, Russian Federation, Hungary, Singapore, France, Netherlands, Sweden, Belgium, United States, Austria, Thailand, Germany, Israel, Poland, Canada, United... and more
European Organisation for Research and Treatment...

Not yet recruiting

Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC (ICARS)

NSCLC Stage IV
Shanghai Henlius Biotech

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

NSCLC Stage IV

China
NYU Langone Health

Recruiting

Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC (IRRADIATE-Lung)

NSCLC Stage IV

United States
ETOP IBCSG Partners Foundation
Mirati Therapeutics Inc.

Recruiting

Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status (ADEPPT)

NSCLC Stage IV | KRAS P.G12C

Ireland, Italy, France, Spain, United Kingdom, Belgium
Zhejiang Cancer Hospital

Recruiting

SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors

NSCLC Stage IV

China
AstraZeneca

Recruiting

Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). (GPS)

Advanced NSCLC

China
IRCCS Policlinico S. Matteo

Recruiting

Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC. (DEDALUS)

NSCLC, Stage III

Italy
Institut für Klinische Krebsforschung IKF GmbH...
AstraZeneca; Thoraxklinik-Heidelberg gGmbH

Recruiting

Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (TRADE-hypo)

NSCLC, Stage III

Germany

3

Subscribe